Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Legal Officer | February 13, 2025 | February 18, 2025 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | See Remarks | May 07, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date February 13, 2025 · Filed February 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,939 |
Ending reported balance
After 2025-02-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-13 · Tax withholding · Disposed 2,135 · Balance 54,353 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Row 2 · 2025-02-14 · Grant · Acquired 56,500 · Balance 110,853 F2: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Row 3 · 2025-02-14 · Tax withholding · Disposed 2,914 · Balance 107,939 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2035-02-13 | Direct | 84,700 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Grant · Acquired 84,700 · Balance 84,700 F3: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
F2: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
F3: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.15 · Expires 2036-03-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the option will vest on January 12, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option will vest on January 12, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 06, 2020
Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 1
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 161,821 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an "RSU") held by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-06 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an "RSU") held by the Reporting Person.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 84,700 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000020 · wk-form4_1739915720.xml · derivative · entry 4 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,700 Underlying: Common Stock · 84,700 shares Expires 2035-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,914 | $3.18 | $9,266.52 |
DisclosureSEC source: 0001662579-25-000020 · wk-form4_1739915720.xml · nonDerivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,939 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 56,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000020 · wk-form4_1739915720.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,853 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,135 | $3.20 | $6,832.00 |
DisclosureSEC source: 0001662579-25-000020 · wk-form4_1739915720.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,353 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000101 · wk-form4_1731446224.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $6.04 | $6,656.08 |
DisclosureSEC source: 0001662579-24-000101 · wk-form4_1731446224.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,488 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000101 · wk-form4_1731446224.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000079 · wk-form4_1726607510.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $6.36 | $4,203.96 |
DisclosureSEC source: 0001662579-24-000079 · wk-form4_1726607510.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,840 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-24-000079 · wk-form4_1726607510.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000024 · wk-form4_1709943540.xml · derivative · entry 4 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001662579-24-000024 · wk-form4_1709943540.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2032-02-13 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 84,850 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000024 · wk-form4_1709943540.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,850 Underlying: Common Stock · 84,850 shares Expires 2031-02-10 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| March 07, 2024 Filed Mar 9, 2024 00:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Disposition to issuerStock Option (Right to Buy) · Derivative | 84,850 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001662579-24-000024 · wk-form4_1709943540.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,850 shares Expires 2031-02-10 F1 · kind: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:07 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 122,800 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001662579-24-000018 · wk-form4_1708034815.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,800 Underlying: Common Stock · 122,800 shares Expires 2034-02-13 F3 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:07 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 27,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000018 · wk-form4_1708034815.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,251 F2 · shares: Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:07 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,735 | $6.53 | $11,329.55 |
DisclosureSEC source: 0001662579-24-000018 · wk-form4_1708034815.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,951 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:22 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000098 · wk-form4_1695165751.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,686 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000038 · wf-form4_167649753180992.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000038 · wf-form4_167649753180992.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,097 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036718 · doc4a.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032515 · doc4.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032515 · doc4.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010207 · doc4.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010207 · doc4.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-055881 · doc4.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,321 Underlying: Common Stock · 12,500 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of this option vested and became exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 12,500 | $50.00 | $625,000.00 |
DisclosureSEC source: 0001209191-21-055881 · doc4.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 12,500 | $4.98 | $62,250.00 |
DisclosureSEC source: 0001209191-21-055881 · doc4.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:49 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-049120 · doc4.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,821 Underlying: Common Stock · 12,500 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of this option vested and became exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:49 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 12,500 | $45.00 | $562,500.00 |
DisclosureSEC source: 0001209191-21-049120 · doc4.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:49 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 12,500 | $4.98 | $62,250.00 |
DisclosureSEC source: 0001209191-21-049120 · doc4.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 84,850 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001209191-21-010708 · doc4.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,850 Underlying: Common Stock · 84,850 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
| May 06, 2020 Filed May 6, 2020 21:06 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001694187-20-000064 · wf-form4_158881356966436.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| May 06, 2020 Filed May 6, 2020 21:06 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0001694187-20-000064 · wf-form4_158881356966436.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| May 06, 2020 Filed May 6, 2020 21:06 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerCommon Stock | 161,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694187-20-000064 · wf-form4_158881356966436.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an "RSU") held by the Reporting Person. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an "RSU") held by the Reporting Person. Read SEC document |
| February 29, 2020 Filed Mar 2, 2020 18:39 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Tax withholdingCommon Stock | 2,845 | $1.50 | $4,267.50 |
DisclosureSEC source: 0001694187-20-000030 · wf-form4_158319236693881.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,821 F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on February 27, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 29, 2020. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 18:21 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Tax withholdingCommon Stock | 5,334 | $1.51 | $8,054.34 |
DisclosureSEC source: 0001694187-20-000013 · wf-form4_158284566350478.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,666 F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on November 25, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 25, 2020. Read SEC document |
| January 12, 2020 Filed Jan 13, 2020 17:27 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694187-20-000008 · wf-form4_157895442165741.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 F1 · shares: Ms. Siegel was awarded 65,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on January 31, 2021 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 25, 2019 Filed Nov 25, 2019 17:25 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694187-19-000078 · wf-form4_157472071053026.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · shares: Ms. Siegel was awarded 75,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest quarterly over one year, subject to the Reporting Person's continued service, with the first tranche vesting on February 25, 2020. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 18:20 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.13 | $0.00 |
DisclosureSEC source: 0001694187-19-000015 · wf-form4_155148240739994.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 18:20 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694187-19-000015 · wf-form4_155148240739994.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Ms. Siegel was awarded 30,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.